Eastern Asia: Market for Medicaments Containing Insulin But Not Antibiotics In Measured Doses 2024

Market Size for Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Eastern Asia

The East Asian prophylactic medicaments containing insulin market rose notably to $X in 2022, growing by X% against the previous year. Overall, consumption enjoyed a strong increase. The level of consumption peaked at $X in 2020; however, from 2021 to 2022, consumption stood at a somewhat lower figure.

Production of Medicaments Containing Insulin But Not Antibiotics In Measured Doses in Eastern Asia

In value terms, prophylactic medicaments containing insulin production expanded markedly to $X in 2022 estimated in export price. Over the period under review, production recorded a resilient increase. The pace of growth appeared the most rapid in 2013 with an increase of X% against the previous year. The level of production peaked at $X.4B in 2020; however, from 2021 to 2022, production remained at a lower figure.

Exports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Exports in Eastern Asia

In 2022, the amount of medicaments containing insulin but not antibiotics in measured doses exported in Eastern Asia shrank to X tons, reducing by X% on the year before. Overall, exports, however, recorded a significant expansion. The growth pace was the most rapid in 2013 with an increase of X% against the previous year. The volume of export peaked at X tons in 2021, and then shrank in the following year.

In value terms, prophylactic medicaments containing insulin exports shrank dramatically to $X in 2022. In general, exports, however, enjoyed a significant increase. The most prominent rate of growth was recorded in 2013 when exports increased by X%. Over the period under review, the exports reached the peak figure at $X in 2021, and then shrank significantly in the following year.

Exports by Country

In 2022, China (X tons) was the key exporter of medicaments containing insulin but not antibiotics in measured doses in Eastern Asia, constituting X% of total export.

China was also the fastest-growing in terms of the medicaments containing insulin but not antibiotics in measured doses exports, with a CAGR of X% from 2012 to 2022. While the share of China (X p.p.) increased significantly, the shares of the other countries remained relatively stable throughout the analyzed period.

In value terms, China ($X) also remains the largest prophylactic medicaments containing insulin supplier in Eastern Asia.

From 2012 to 2022, the average annual rate of growth in terms of value in China totaled X%.

Export Prices by Country

In 2022, the export price in Eastern Asia amounted to $X per ton, declining by X% against the previous year. Export price indicated a moderate expansion from 2012 to 2022: its price increased at an average annual rate of X% over the last decade. The trend pattern, however, indicated some noticeable fluctuations being recorded throughout the analyzed period. Based on 2022 figures, prophylactic medicaments containing insulin export price decreased by X% against 2020 indices. The most prominent rate of growth was recorded in 2020 when the export price increased by X% against the previous year. As a result, the export price attained the peak level of $X per ton. From 2021 to 2022, the export prices failed to regain momentum.

As there is only one major export destination, the average price level is determined by prices for China.

From 2012 to 2022, the rate of growth in terms of prices for China amounted to X% per year.

Imports of Medicaments Containing Insulin But Not Antibiotics In Measured Doses

Imports in Eastern Asia

In 2022, the amount of medicaments containing insulin but not antibiotics in measured doses imported in Eastern Asia fell dramatically to X tons, dropping by X% against the year before. Over the period under review, imports, however, continue to indicate a relatively flat trend pattern. The growth pace was the most rapid in 2013 when imports increased by X%. Over the period under review, imports attained the peak figure at X tons in 2019; however, from 2020 to 2022, imports failed to regain momentum.

In value terms, prophylactic medicaments containing insulin imports shrank significantly to $X in 2022. Overall, imports continue to indicate a perceptible decrease. The pace of growth was the most pronounced in 2021 when imports increased by X%. The level of import peaked at $X in 2013; however, from 2014 to 2022, imports remained at a lower figure.

Imports by Country

The purchases of the three major importers of medicaments containing insulin but not antibiotics in measured doses, namely Japan, China and South Korea, represented more than two-thirds of total import. It was distantly followed by Taiwan (Chinese) (X tons), comprising a X% share of total imports. Hong Kong SAR (X tons) followed a long way behind the leaders.

From 2012 to 2022, the biggest increases were recorded for Taiwan (Chinese) (with a CAGR of X%), while purchases for the other leaders experienced more modest paces of growth.

In value terms, the largest prophylactic medicaments containing insulin importing markets in Eastern Asia were Japan ($X), China ($X) and South Korea ($X), together accounting for X% of total imports. Taiwan (Chinese) and Hong Kong SAR lagged somewhat behind, together comprising a further X%.

Taiwan (Chinese), with a CAGR of X%, saw the highest rates of growth with regard to the value of imports, in terms of the main importing countries over the period under review, while purchases for the other leaders experienced more modest paces of growth.

Import Prices by Country

The import price in Eastern Asia stood at $X per ton in 2022, declining by X% against the previous year. Over the period under review, the import price saw a deep setback. The growth pace was the most rapid in 2021 when the import price increased by X%. The level of import peaked at $X per ton in 2012; however, from 2013 to 2022, import prices remained at a lower figure.

There were significant differences in the average prices amongst the major importing countries. In 2022, amid the top importers, the country with the highest price was China ($X per ton), while South Korea ($X per ton) was amongst the lowest.

From 2012 to 2022, the most notable rate of growth in terms of prices was attained by South Korea (X%), while the other leaders experienced mixed trends in the import price figures.

Source: IndexBox Platform

Frequently Asked Questions (FAQ) :